⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MIRM News
Mirum Pharmaceuticals, Inc. Common Stock
Form 8-K
sec.gov
MIRM
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
businesswire.com
MIRM
Form 8-K
sec.gov
MIRM
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
businesswire.com
MIRM
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
businesswire.com
MIRM
Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
businesswire.com
MIRM
Form 8-K
sec.gov
MIRM
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
businesswire.com
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
MIRM
Egetis Appoints Tiago Nunes as Chief Medical Officer
accessnewswire.com
MIRM